Share information
226.90 €
-1.86 %
04/05/2026 12:30
-1.86 %
Open
High
Low
Volume
230.40 €
230.40 €
225.90 €
21,348
Latest News
03-May-2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)
30-Apr-2026
UCB’s General Meeting of Shareholders 2026
24-Apr-2026
Acquisition of own shares